Poziotinib is a novel, oral, quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the HER family of tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4), as well as HER receptor mutations; this in turn can lead to inhibition of the proliferation of tumor cells that overexpress these receptors.
Route of Administration
Mode of Action
In the U.S., breast cancer is the second most common cancer in women after skin cancer. In 2016, it is estimated that there will be 246,660 new cases of female breast cancer and an estimated 40,450 people will die of this disease. It is estimated there are over 3 million women living with breast cancer, and 89.7% of these women will survive at least 5 years.